Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Sinovac Strikes Deal with Bio Farma to Produce CoronaVac for Indonesia
Bio Farma, a state-owned company, started a 1,620 person Phase III trial of CoronaVac earlier this month. Sinovac said it expects the manufacturing agreement to facilitate development of CoronaVac and to increase cooperation between the two companies in the future.
In June, Sinovac announced it would stage a Phase III trial of CoronaVac in
Sinovac produces vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, Quadrivalent Influenza vaccine (“QIV”), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps.
The company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, and the COVID-19 vaccine.
See our other articles on Sinovac.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China